文献速递前列腺癌

ERG表达可预测多西他赛联合雄激素剥夺治疗在高危局限性和转移性激素敏感性前列腺癌中的获益:两项GETUG 3期试验分析

The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
PubMed 文献 · Eur Urol Oncol · 2024-07-20

基于GETUG 12和GETUG 15两项3期试验治疗前活检标本,评估ERG等标志物与多西他赛疗效的关系。汇总分析显示,多西他赛改善ERG阳性患者的无失败生存(HR 0.58;p=0.03),对ERG阴性患者无获益(HR 1.08;p=0.72),交互作用p=0.056。Ki67与更差的无复发生存相关(HR 1.72;p=0.0092)。

要点

  • ERG阳性激素敏感性前列腺癌患者接受多西他赛联合ADT的无失败生存优于单用ADT(HR 0.58;p=0.03)。
  • ERG阴性患者多西他赛联合ADT无失败生存无显著改善(HR 1.08;p=0.72)。
  • Ki67与更差的无复发生存相关(HR 1.72;p=0.0092),可能作为预后因素。

核心结论

  • Ki67可能作为激素敏感性前列腺癌的预后因素。
  • ERG表达似乎可预测高危局限性和转移性激素敏感性前列腺癌对多西他赛的反应。

研究设计与样本

  • 对GETUG 12(高危局限性前列腺癌)和GETUG 15(转移性激素敏感性前列腺癌)两项随机3期试验的治疗前前列腺活检标本进行分析。
  • GETUG 12样本进行Ki67、PTEN、RB及磷酸化RB免疫组化染色;GETUG 12和GETUG 15样本进行ERG染色。
  • 采用单因素和多因素分析(校正其他已验证预后因素)评估标志物与结局的关联。

主要发现

  • GETUG 12中,Ki67与更差的无复发生存相关(HR 1.72;p=0.0092)。
  • 两项试验汇总分析(交互作用p=0.056)显示,多西他赛为基础化疗改善ERG阳性患者的无失败生存(HR 0.58;p=0.03),但未改善ERG阴性患者(HR 1.08;p=0.72)。
  • GETUG 12 ERG阳性亚组中,单用ADT的中位无复发生存为7.79年,ADT+多西他赛组未达到。
  • GETUG 12 ERG阴性亚组中,单用ADT的中位无进展生存为7.79年,ADT+多西他赛组为7.08年。
  • GETUG 15 ERG阳性亚组中,单用ADT的中位无进展生存为10.7个月,ADT+多西他赛组为18.8个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Docetaxel has become a standard component of care for advanced prostate cancer (PC); however, its benefits are not universal among patients. A subset of PC cases exhibit TMPRSS2-ERG gene fusion, resulting in ERG overexpression in tumors. Our aim was to assess biomarkers for docetaxel efficacy in men with hormone-sensitive PC (HSPC). METHODS: Pretreatment prostate biopsies were obtained from participants in two randomized phase 3 clinical trials investigating docetaxel in high-risk localized PC (GETUG 12) and metastatic HSPC (GETUG 15). Immunohistochemistry staining for Ki67, PTEN, RB, and phosphorylated RB was conducted for GETUG 12 samples, and ERG staining for GETUG 12 and GETUG 15 samples. We examined biomarker association with outcomes using univariate and multivariable analyses adjusted for other validated prognostic factors. KEY FINDINGS AND LIMITATIONS: Among GETUG 12 patients, Ki67 was associated with a worse relapse-free survival (RFS; hazard ratio [HR] 1.72; p = 0.0092). A pooled analysis for the two trials (pinteraction = 0.056) revealed that docetaxel-based chemotherapy improved failure-free survival for patients with ERG-positive cancer (HR 0.58; p = 0.03), but not patients with ERG-negative cancer (HR 1.08; p = 0.72). In the ERG-positive subgroup in GETUG 12 (high-risk localized PC), median RFS was 7.79 yr with androgen deprivation therapy (ADT) alone, and was not reached with ADT + docetaxel. In the ERG-negative subgroup, median progression-free survival (mPFS) was 7.79 yr with ADT alone versus 7.08 yr with ADT + docetaxel. In the ERG-positive subgroup in GETUG 15 (metastatic HSPC), mPFS was 10.7 mo with ADT alone versus 18.8 mo with ADT + docetaxel. In the ERG-negative subgroup, mPFS was 10.6 mo with ADT alone versus 13.2 mo with ADT + docetaxel. CONCLUSIONS AND CLINICAL IMPLICATIONS: Ki67 may serve as a prognostic factor in HSPC, while ERG expression appears to predict a response to docetaxel in both high-risk localized and metastatic HSPC. PATIENT SUMMARY: We assessed factors that could predict outcomes after docetaxel chemotherapy in patients with advanced prostate cancer. We found that expression of a protein called ERG can predict a good response to docetaxel in these patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rajpar S, Ibrahim T, Carmel A, et al. The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials. Eur Urol Oncol. 2024. PMID: 39034169. doi:10.1016/j.euo.2024.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。